ArticleAsian Pacific journal of cancer prevention : APJCP2024
Assessment of in vitro and in silico Antiproliferative Effects of p-Cymene and Its Naturally Occurring 7-Oxygenated Derivatives on Human Cancer Cell Lines.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Urinary Volatilomic Signatures for Non-Invasive Detection of Lung Cancer: A HS-SPME/GC-MS Proof-of-Concept Study.International journal of molecular sciences · 2026Article
- Impact of Extended Natural Drying on Yields, Constituents, and Biological Activities of Artemisia monosperma Delile Essential Oils.Chemistry & biodiversity · 2026Article
- Thymus serpyllum extract exerts anticancer activities against colorectal cancer by modulating metastasis, cell cycle arrest, and apoptosis.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the in vitro and silico antiproliferation of p-cymene, cumin aldehyde, cuminic acid, and cuminol against human cancer cell lines (HCCLs). The sodium salt of the organic acid was included after synthesis.
methodsThe quality of the compounds was verified using analytical methods. A primary screening of the compounds at 100 µM was conducted (n=6) on nine HCCLs (SK-MEL-28, K562, Lucena, Jurkat, Caco-2, MDA-MB-231, THP-1, U87-MG, and Calu-3) and HEK-293 through the MTT method after 48h-incubation. The viability curve and apoptotic and necrotic cell populations of cumin aldehyde-treated Calu-3 cells were determined. The statistical significance relative to the vehicle was evaluated using ANOVA and Dunnett. The possibility of being active (Pa) on HCCLs and biological targets was assessed in silico using CLC-Pred. Moreover, the ADMET properties were predicted using three servers.
resultsOnly cumin aldehyde induced a low and significant (31±5%, p<0.001) in vitro antiproliferation, and even then, only on the Calu-3 line (IC50 650 µM). Only necrosis was significant (p<0.01) with 300 µM after 24h. The absence (p>0.05) of in vitro activity on the other HCCLs corroborated the low in silico probability of being active (Pa≤0.33), except for cumin aldehyde on the MDA-MB-231 line (Pa=0.47). P-cymene was proven to be the most toxic compound to human health.
conclusionExcepting cumin aldehyde, the lack of the antiproliferation potential of these p-cymene derivatives was extensively demonstrated for the first time. Cuminaldehyde induced toxicity in a lung adenocarcinoma line, corroborating the literature. Six selective and three specific cell lines were proposed to evaluate the anticancer activity of the compounds in addressed studies, mainly involving those with Pa≥0.50. The inhibition of five targets seems to play a role in inducing HCCL antiproliferation. The ADMET estimated that cumin aldehyde, cuminol, and sodium cuminate are the safest compounds for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.